AbbVie’s Azita Saleki exercises options on 13,481 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AbbVie Inc. EVP and Chief Operations Officer Azita Saleki exercised options covering 13,481 shares at $61.36 per share on November 16, 2026; the reported option balance afterward was 23,935 shares. A separate common-stock row reports acquisition of 23,935 shares at $61.36 per share. The report also records 13,481 shares delivered or withheld for payment of exercise price or tax liability, at a weighted-average price of $298.55 across transactions from $298.55 to $298.64. No Rule 10b5-1 plan is reported. A profit sharing trust held 2,764 shares indirectly through the AbbVie Savings program as of November 16, 2026.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (Right to Buy) F3 | 13,481 | $0.00 | $0.00 |
| Exercise | Common Stock, $0.01 par value | 23,935 | $61.36 | $1.47M |
| Exercise Price or Tax Liability | Common Stock, $0.01 par value F1 | 13,481 | $298.55 | $4.02M |
| Holding | Common Stock, $0.01 par value F2 | -- | -- | -- |
Footnotes (3)
- F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.55 to $298.64, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. Balance in AbbVie Savings program as of November 16, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
- F3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 15,957 on February 16, 2018, 15,956 on February 16, 2019, and 15,957 on February 16, 2020.
Key Figures
Key Terms
weighted average price financial
Rule 10b5-1 plan regulatory
Rule 16b-3 regulatory
dividend reinvestment feature financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AbbVie options did Azita Saleki exercise, and at what price?
AI-generated analysis. How Rhea-AI works. Not financial advice.